With "Precision Medicine" a concept for disease treatment and prevention has emerged that takes into account an individual's own genome, specific environment, and particular lifestyle.
Scientists foresee that in coming years "Precision Medicine" will expand to many areas of healthcare, with medical decisions, treatments, practices, or products being tailored to the individual patient's needs. The goal of ongoing research is to ultimately allow physicians to base predictions on evidence that comes from the individual's own molecular data and to assess which treatment and which prevention strategy for a particular disease will work in which groups of patients / people.
We plan to organize a conference with oral contributions from internationally renowned scientists and clinicians whose contributions shall shed light on the potentials and benefits of "Precision Medicine" approaches. New research concepts and already existing clinical experience shall be shared as well as translational aspects be discussed.
Christoph Borchers received his PhD from the University of Konstanz, Germany in 1996. From 2001 to 2006, he was the director of the University of North Carolina-Duke Proteomics Facility, Chapel Hill, NC, holding a faculty position at the UNC Medical School. From 2006 to 2019, he was a Professor in the Department of Biochemistry and Microbiology, and Director of the University-Genome British Columbia Proteomics Centre at the University of Victoria, British Columbia, Canada, where he held the Rix BC Leadership Chair in Biomedical and Environmental Proteomics. Dr. Borchers is currently a Professor in the Department of Oncology at McGill University, Montreal, Quebec, Canada, and holds the Segal Chair in Molecular Oncology. He is also the founder and Director of the Segal Cancer Proteomics Centre at the Lady Davis Institute, Jewish General Hospital, McGill University. His research involves proteomics and metabolomics technologies for clinical diagnostics and structural proteomics.
Bernd Gerber studied Medicine at University of Rostock, Germany and an MD in 1985 and subsequently became a fellow at the Institute of Physiology, University of Rostock for one year. In 1990, he became a Medical specialist in Obsterics/Gyaenocology and in 1993, he became the Head of the Division of Senology, Plastic Aesthetic and Reconstructive Surgery in Gynecology, University of Rostock. He received his PhD in 1994. From 2002 to 2005, he was the leading head physician at LMU Munich, Germany. Since 2005, he is the Director of the Department of Obsterics/Gyaenocology, University of Rostock with subspecialisation in Gynaecologic Oncology, Head of the certified Breast Center, and Head of the certified Gynecological Cancer Center. He has done habilitation in the following instituitions: Vanderbilt University Nashville TN, USA; MD Anderson, Houston TX, USA; Harvard University Boston MA, USA; INCA, Clinic of plastic and esthetic surgery, Rio de Janeiro, Brasilien; The Breast Center „Van Nuys”, Los Angeles CA, USA; Emory University, Dept. Plastic & Reconstruct. Surgery, Atlanta GA, USA; MD Anderson, Houston TX, USA; and West Olympic Surgery Center, Los Angeles CA, USA. He is member of the following organizations: Leopoldina – National Academy of Science; American Society of Clinical Oncology; German Society of Obsterics/Gyaenocology; German Society of Senology; and German Cancer Society. He is currently the Director of Women Hospital, University of Rostock at Klinikum Südstadt, Rostock, Germany. His research focuses mainly on gynaecologic oncology.
David Goodlett has spent his career using mass spectrometry to solve biomedical problems via novel technology and software developments. He has been active in a variety of fields including medicine, oceanography, pharmacy, microbiology, proteomics (including clinical applications), lipidomics, and protein & glycolipid structure-function relationships publishing over 250 papers. He has been a Professor at the University of Maryland (2013-present) and the University of Washington (2004-2012) as well as first Director of Proteomics at the Institute for Systems Biology (2000-2003). From 2012-2016 he was a Finland Distinguished Professor; www.youtube.com/watch. He is an Editor at Rapid Communications in Mass Spectrometry who recently published an interview with him onlinelibrary.wiley.com/doi/abs/10.1002/rcm.8187 and since 2007 he has been a co-organizer of www.msbm.org. In 2018 he joined the University of Gdansk’s International Centre for Cancer Vaccine Science (ICCVS) as a Visiting Professor to set up proteomics within the centre.
Markus Kalkum is a Professor in the Department of Molecular Imaging & Therapy; and the Director of the Mass Spectrometry and Proteomics Core Facility, at the Beckman Research Institute of City of Hope in Los Angeles, California. In his research laboratory, Dr. Kalkum is developing novel diagnostic assays for microbial diseases, researches probiotic immunomodulators, and mycosis vaccines. He is known for a very sensitive detection assay for botulinum neurotoxin. He recently discovered a variant of the folate cycle in Lactobacillus reuteri that gives rise to a “two carbon metabolism” instead of the conventional “one carbon” cycle. Compounds resulting from the two carbon folate cycle can modulate immune responses. Dr. Kalkum holds a Ph.D. in Chemistry, Biology, and Pharmacology from the Freie Universität Berlin, Germany. Previously, he had worked at the Max-Planck Institute for Molecular Genetics in Berlin, and conducted postdoctoral research at the Rockefeller University in New York City.
Ayodele Alaiya obtained his MB.BS in Ilorin, MPH in Dundee, PhD in Stockholm, and FRCPath London. He is currently a Senior Scientist/Head, Proteomics Unit, and Director, Stem Cell and Tissue Re-Engineering Program at King Faisal Specialist Hospital & Research Center in Riyadh, Saudi Arabia. Previously, he held positions as Scientist at Cancer Center, Karolinska Hospital (CCK), Stockholm, Sweden. His research interest includes basic life science, translational clinical proteomics, and biomarker discovery for clinical applications for different diseases in general and cancer and stem cell subtypes in particular. He has more than 20 years’ research experience in cancer and applied proteomics with over 50 scientific publications in peer reviewed journals and two book chapters. At KFSHRC Proteomics Unit, Dr. Alaiya has established the first fully functional Proteomics Lab in Saudi Arabia that is fully engaged in basic and translational clinical research. His group is keen to develop new innovative projects and collaborations with national and international research groups hopefully generating new information and testing the real value of the technology in clinical practice towards precision/personalized medicine.
Charles Ayensu Okai, studied Chemistry and obtained his Master's degree in Pharmaceutical Chemistry from the Kwame Nkrumah University of Science and Technology, Ghana in 2006. He is currently a doctoral student working in the research group of Prof. Dr. Michael Glocker at Proteome Center Rostock, University of Rostock, Germany. His research area is on the development of screening/diagnostics approaches for intrauterine growth restriction (IUGR) in early pregnancies with special interest in applying affinity-mass spectrometry methods. He is a German Academic Exchange Service (DAAD) scholarship holder.
Evangeline Obodai studied Biochemistry, and Medical Microbiology from the University of Ghana. She later obtained her PhD in Molecular Biology and Virology from the Free University, Berlin, Germany. She has a lot of experience in biomedical research of public health importance, and she is currently a Research Fellow in the Department of Virology, Noguchi Memorial Institute Medical Research, University of Ghana. Her research interests include molecular evolution studies of respiratory viruses, and epidemiology of viral respiratory infections, and surveillance for emerging and remerging zoonotic infections and diseases of viral origin. She also has a keen interest in cancer studies and vaccine clinical trials.
James Aboagye obtained his Ph.D. from the Department of Microbiology and Immunology, National University of Singapore. He is currently a Research Scientist with the Virology Department, Noguchi Memorial Institute for Medical Research. His research focuses on characterizing pathogen-host interaction as well as host genetic modifications associated with infections for designing and developing effective drugs and therapeutic options. Also, he is interested in identifying and characterizing emerging and re-emerging viruses circulating within humans and animals.
Kwabena Frimpong-Manso Opuni studied pharmacy and subsequently obtained his MSc. Pharmaceutical Analysis & Quality Control degree from Kwame Nkrumah University of Science & Technology, Ghana in 2005. He is a certified Project Management Professional (PMP) since 2008. In 2016, he received his PhD from Proteome Center Rostock, University of Rostock, Germany, which focused on structural and functional characterization of clinically relevant autoantigens, autoantibodies and antigen-antibody interaction using mass spectrometric and computational epitope mapping and prediction methods. His PhD work was supported by a stipend from the German Academic Exchange Service (DAAD). Currently, he is a Senior Lecturer and Head, Department of Pharmaceutical Chemistry, School of Pharmacy, University of Ghana. His current research involves the application of biocomputational, chemometric and mass spectrometric based proteomic approaches to improve diagnostics for malaria and autoimmune diseases. In 2019, he was awarded the DAAD Re-Invitation Program for former DAAD Scholarship for 3-month postdoctoral fellowship at Proteome Center Rostock, University of Rostock, Germany.
Michael O. Glocker studied Chemistry at the University of Konstanz, Germany, where he graduated in Organic Chemistry. In his subsequent work (Post Doc. at Oregon State University, USA; Habilitation in Konstanz, Germany), he combined bioanalytical methods, particularly modern mass spectrometry techniques, with biochemical protein modification reactions to analyze protein structures, protein-protein interactions, and protein folding intermediates. In 1999, Michael O. Glocker received the call from the University of Rostock, Germany, for the appointment of the first German professorship devoted to Proteome research. Since then he is director of the Proteome Center Rostock. His current research is focused on the development of advanced mass spectrometric methods in conjunction with biochemical modification reactions for the characterization of protein structures and protein-protein interactions, for antibody-epitope mapping, and for determination of regulatory and signaling pathways in a Systems Biology approach, opening novel entries into Precision Medicine.
Nicholas I. Nii-Trebi studied Biochemistry at the University of Ghana, Legon where he obtained a Master of Philosophy degree in Biochemistry in 2003. With special interest in Systems Biology, he subsequently worked as Principal Research Assistant in the Virology Department of the Noguchi Memorial Institute for Medical Research of the University of Ghana, where he engaged in species characterization of clinically relevant viruses, HIV drug efficacy testing and drug resistance surveillance. In 2007, he took appointment as lecturer in Virology at the Department of Medical Laboratory Sciences of the School of Biomedical and Allied Health Sciences, University of Ghana. In 2018, he received his PhD in Medical Science from the Kumamoto University, Japan. His PhD research focused on the role of host genomic factors in HIV replication and disease outcome. He is currently a Senior Lecturer; and his research explores the impact of human leukocyte antigens (HLA) as well as recently identified HIV restriction factor CHD1L as potential therapeutic targets to suppress HIV replication with aim to provide robust genotype-phenotype information useful for improvement of patient management of HIV in Africa.
Seth Kwabena Amponsah had his first degree from the University of Ghana in Biochemistry and Nutrition. He continued with an MPhil and PhD both from University of Ghana. He completed his PhD in 2015 with a study on improving diagnosis and treatment of neonatal sepsis at the neonatal intensive care unit, Korle-Bu Teaching Hospital. This PhD was supported by the Health Platform of Building Stronger Universities (BSU) in Developing Countries Initiative, a Danish International Development Agency (DANIDA) funded collaboration between Danish Universities and University of Ghana. His research interest are pharmacokinetic studies in human and animal models: population pharmacokinetic modeling; non-compartment pharmacokinetic estimation; pharmacokinetic evaluation of new drug formulations (micro-particles, nano-particles, etc); drug-drug (herb) interaction and possible pharmacokinetic consequence. He is also interested in antimicrobial stewardship: prudent use of antimicrobials, antimicrobial level monitoring, and efficacy of antimicrobials in patients. In July 2019, he was awarded a Post-Doctoral Fellowship under Building Stronger Universities Phase III (Malaria and Hemoglobinopathies). He is currently a Senior Lecturer and Head of Medical Pharmacology, University of Ghana Medical School.
Science Advisory Board
Michael O. Glocker studied Chemistry at the University of Konstanz, Germany, where he graduated in Organic Chemistry. In his subsequent work (Post Doc. at Oregon State University, USA; Habilitation in Konstanz, Germany), he combined bioanalytical methods, particularly modern mass spectrometry techniques, with biochemical protein modification reactions to analyze protein structures, protein-protein interactions, and protein folding intermediates. In 1999 Michael O. Glocker received the call from the University of Rostock, Germany, for the appointment of the first German professorship devoted to "Proteome research". Since then he is director of the Proteome Center Rostock. His current research is focused on the development of advanced mass spectrometric methods in conjunction with biochemical modification reactions for the characterization of protein structures and protein-protein interactions, for antibody-epitope mapping, and for determination of regulatory and signaling pathways in a Systems Biology approach, opening novel entries into "Precision Medicine".
- Kwabena Frimpong-Manso Opuni
Proteome Center Rostock
University of Rostock
Department of Pharmaceutical Chemistry
School of Pharmacy
University of Ghana
- Kwaku Danso Agyei
Klinikum Südstadt Rostock